...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Randomized clinical trial with two doses (100 and 40 ml) of Stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B.
【24h】

Randomized clinical trial with two doses (100 and 40 ml) of Stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B.

机译：随机临床试验有两个剂量(100和40毫升)的强Neo-Minophagen C在中国慢性乙型肝炎患者。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Stronger Neo-Minophagen C (SNMC) is an intravenous drug with glycyrrhizin as the principal ingredient. The efficacy and safety of SNMC at two doses were evaluated on 194 patients with chronic hepatitis B in nine hospitals in China. They all had serum levels of alanine aminotransferase (ALT) exceeding twice the upper limit of normal (>80 IU/l). SNMC daily 100 and 40 ml were given for 4 weeks to the patients randomized into Group A (N=99) and Group B (N=95), respectively. Thereafter, all patients received oral glycyrrhizin (GLYCYRON Tab) 9 tablets a day for an additional 4 weeks. Primary end-point was ALT<1.5 times the upper limit of normal (60 IU/l) at completion of the 8-week therapy, and it was achieved by 73 patients (74%) in Group A and 74 (79%) patients in Group B; normalization of ALT levels (<40 IU/l) was accomplished in 58 (58%) and 54 (57%) patients in Groups A and B, respectively. SNMC was withdrawn in four (2%) patients due to mild and reversible side effects. Based on these results, SNMC is safe and efficacious in lowering or normalizing ALT levels in patients with chronic hepatitis B in China, and an induction dose of 40 ml daily is efficient in achieving maximal effects.
机译：强Neo-Minophagen C (SNMC)是一种静脉注射药物以甘草酸为本金成分。两个剂量评估194例慢性乙型肝炎在中国九医院。他们都有血清丙氨酸的含量转氨酶(ALT)超过上限的两倍限制正常的(> 80 IU / l)。毫升有4周的病人随机分为A组(N = 99)和B组分别(N = 95)。收到口服甘草甜素(GLYCYRON选项卡)9平板电脑一天额外的4周。端点是ALT <上限的1.5倍正常(60 IU / l)完成8周治疗,通过73名患者(74%)在A组和74例(79%)患者B组;ALT正常化水平(< 40 IU / l)在58完成(58%)和54例(57%)患者分别组A和B。在四个(2%)病人由于温和的和可逆的副作用。安全、有效的降低或正常化在慢性乙型肝炎患者ALT水平在中国,和一个感应每日剂量为40毫升效率达到最大效果。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号